Neuburgh Advisers’s Alexion Pharmaceuticals ALXN Stock Holding History

Neuburgh Advisers’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$843K	Sell	8,602 -578	-6%	-$65.2K	0.03%	353
2019 Q2	$1.2M	Sell	9,180 -3,128	-25%	-$403K	0.04%	300
2019 Q1	$1.66M	Buy	12,308 +3,026	+33%	+$376K	0.06%	224
2018 Q4	$904K	Sell	9,282 -170	-2%	-$20.1K	0.04%	285
2018 Q3	$1.31M	Buy	9,452 +102	+1%	+$12.8K	0.04%	248
2018 Q2	$1.16M	Buy	9,350 +1,258	+16%	+$147K	0.04%	273
2018 Q1	$902K	Sell	8,092 -340	-4%	-$40.6K	0.03%	285
2017 Q4	$1.01M	Buy	8,432 +2,346	+39%	+$286K	0.04%	281
2017 Q3	$854K	Sell	6,086 -1,088	-15%	-$148K	0.03%	302
2017 Q2	$873K	Buy	7,174 +578	+9%	+$67.3K	0.03%	293
2017 Q1	$800K	Buy	6,596 +1,020	+18%	+$132K	0.03%	298
2016 Q4	$682K	Buy	+5,576	New	+$682K	0.03%	296

Other funds holding ALXN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Neuburgh Advisers's ALXN Position: Q3 2019 in Review

Neuburgh Advisers reduced its Alexion Pharmaceuticals (ALXN) stake by 6.3% in Q3 2019, selling an estimated $65.2K and leaving 8,602 shares worth $843K. The position accounts for 0.03% of the portfolio, ranked #353.

Neuburgh Advisers first reported a position in ALXN in Q4 2016 and has held it in 12 quarters since. The position peaked at $1.66M in Q1 2019. 646 funds tracked by Wall St. Rank hold ALXN as of Q3 2019.

Neuburgh Advisers held 8,602 shares of Alexion Pharmaceuticals worth $843K as of Q3 2019.
Neuburgh Advisers sold 578 Alexion Pharmaceuticals shares in Q3 2019, an estimated $65.2K.
Alexion Pharmaceuticals made up 0.03% of Neuburgh Advisers's portfolio in Q3 2019, its #353 holding.
Neuburgh Advisers first reported a position in Alexion Pharmaceuticals in Q4 2016 and has held it in 12 quarters since.
Neuburgh Advisers's Alexion Pharmaceuticals position peaked at $1.66M in Q1 2019.
646 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2019.

Based on Neuburgh Advisers's 13F filing for Q3 2019, filed 14 Nov 2019.